Pharmacy & Therapeutics - March 2008 - (Page 180) DRUG FORECAST continued from page 136 EDITORIAL continued from page 127 tious Diseases Pharmacists Newsletter, Spring 2007;8–20. FDA approves new drug to treat complicated urinary tract and intra-abdominal infections. Available at: www.fda.gov/ bbs/topics/NEWS/2007/NEW01728.html. Accessed December 10, 2007. Doripenem S-4661. ADIS R&D Profile. Drugs R&D 2003;4(6):363–365. Doribax (doripenem), package insert. Raritan, NJ: Ortho-McNeil; October 2007. Micromedex® Healthcare Series (Internet Database), version 5.1. Greenwood Village, CO: Thomson Micromedex; 2008. Data on file. Ortho-McNeil Janssen Scientific Affairs, LLC, 2007. Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of doripenem versus imipenem for ventilator-associated pneumonia. Poster, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 17–20, 2007. Postier R, Clavel M, Prokocimer P, et al. Efficacy of doripenem versus imipenem in patients with ventilator-associated pneumonia and high disease severity. Poster, 45th Annual Meeting of Infectious Diseases Society of America, San Diego, October 4–7, 2007. Rea-Neto A, Niederman M, Lee M, et al. Efficacy and safety of intravenous doripenem versus piperacillin/tazobactam in nosocomial pneumonia. Poster, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 17–20, 2007. Data on file. Johnson & Johnson Pharmaceutical Research & Development, LLC, 2006. Lunde JL, Nelson RE, Storandt HF. Acute seizure in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy 2007;27:1202–1205. Mori H, Takahashi K, Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev 2007; 39:647–657. Spriet I, Goyens J, Meersseman W, et al. Interaction between valproate and meropenem: A retrospective study. Ann Pharmacother 2007;41:1130–1136. Weiss ME, Adkinson NF. Beta-lactam allergy. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 6th ed. New York: Elsevier Churchill Livingstone; 2005:318–326. Anderson DL. Doripenem. Drugs Today 2006;42;399–404. Strategies to Address Antimicrobial Resistance Act (STAAR). Available at: www. idsociety.org/STAARAct.htm. Accessed December 11, 2007. Bad bugs, no drugs as antibiotic discovery stagnates: A public crisis brews. Infectious Diseases Society of America; July 2004. Available at: www.idsociety. org/WorkArea/showcontent.aspx?id= 5554. Accessed December 11, 2007. I The potential advantages of doripenem include a slightly better in vitro activity against P. aeruginosa and Acinetobacter spp., which may include some carbapenem-resistant strains.18 However, the clinical significance of these data is yet to be determined. Doripenem was also studied via extended infusion, which has been gaining popularity as a result of the pharmacokinetic and pharmacodynamic advantages over bolus dosing. These data are promising; extended infusion was found to be effective and well tolerated in ventilator-associated pneumonia patients. At this time, however, these data are not included in the agent’s prescribing information, which continues to evolve. The data also suggest that doripenem, of all the carbapenems, may have the greatest ability to prevent the emergence of carbapenem-resistant mutant strains, with the potential to address the widespread problem of resistance echoed by the Infectious Disease Society of America and, most recently, by the Strategies to Address Antimicrobial Resistance Act, which was introduced in Congress in late 2007.19,20 Although doripenem has been approved in Japan since 2005, more data are needed to best define its role in therapy and to identify potential problems that might emerge with expanded use, such as clarifying dosing recommendations in patients with a CrCl below 10 mL/minute and in patients on dialysis. On the basis of the current in vitro and clinical data, doripenem may prove useful for hospitalized patients with serious infections who need broad-spectrum antibacterial coverage or who have an infection with a highly resistant pathogen. 5. 6. 7. 8. 9. 10. 11. every P&T committee member. I hope that all of our readers will study and debate the merits of the Mathematica report. I also think our own organizations could do more to educate the public about diabetes prevention. With the report in mind, what would you now tell a presidential candidate attending your P&T committee meeting about opportunities for government leaders to change diabetes care? Readers can obtain a copy of the Mathematica report by calling 202-484-9220 or by visiting the company’s Web site, www.mathematica-mpr.com. As always, I am interested in your views. You can reach me at my e-mail address, david.nash@jefferson.edu, and you can also visit my new blog at http:// departmentofhealthpolicy. blogspot.com. REFERENCE 1. An Opportunity for Federal Leadership in Changing Diabetes: A Study of Federal Spending on Diabetes. Washington, DC: Mathematica Policy Research, Inc.; June 2007. I 12. 13. 14. COMING SOON TO P&T EDITORIAL “Slaves to Medicine” David B. Nash, MD, MBA DRUG FORECAST The Selegiline Transdermal System: A Therapeutic Option For the Treatment of Major Depressive Disorder 15. 16. REFERENCES 1. Zhanel G, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67(7):1027–1052. 2. Jones R, Huynh H, Biedenbach D. Activities of doripenem (S-4661) against drugresistant clinical pathogens. Antimicrob Agents Chemother 2004;48(8):3136–3140. 3. Nakashima M, Kato T, Kimura Y, et al. S-4661, a new carbapenem: IV. Pharmacokinetics in healthy volunteers. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, 32, 1994. 4. Nicasio AM, Kuti JL, Nicolau DP. The current state of multiple-drug resistant gram-negative bacilli in North America: Insights from the Society of Infectious Diseases Pharmacists. Society of Infec- 17. 18. 19. Lois Jessen, MS, PharmD; Lawrence J. Kovalick, PharmD; and Albert J. Azzaro, PhD FEATURE ARTICLE Drug Utilization Evaluation: Prescribing Trends with Daptomycin (Cubicin) for the Treatment of Gram-Positive Infections 20. Noreen H. Chan Tompkins, PharmD, and Stephen J. Harnicar, PharmD 180 P&T® • March 2008 • Vol. 33 No. 3 http://www.fda.gov/bbs/topics/NEWS/2007/NEW01728.html http://www.fda.gov/bbs/topics/NEWS/2007/NEW01728.html http://www.mathematica-mpr.com http://departmentofhealthpolicy.blogspot.com http://departmentofhealthpolicy.blogspot.com http://www.idsociety.org/STAARAct.htm http://www.idsociety.org/STAARAct.htm http://www.idsociety.org/WorkArea/showcontent.aspx?id=5554 http://www.idsociety.org/WorkArea/showcontent.aspx?id=5554 http://www.idsociety.org/WorkArea/showcontent.aspx?id=5554
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.